keyword
https://read.qxmd.com/read/38256908/a-novel-combined-dry-powder-inhaler-comprising-nanosized-ketoprofen-embedded-mannitol-coated-microparticles-for-pulmonary-inflammations-development-in-vitro-in-silico-characterization-and-cell-line-evaluation
#1
JOURNAL ARTICLE
Heba Banat, Ildikó Csóka, Dóra Paróczai, Katalin Burian, Árpád Farkas, Rita Ambrus
Pulmonary inflammations such as chronic obstructive pulmonary disease and cystic fibrosis are widespread and can be fatal, especially when they are characterized by abnormal mucus accumulation. Inhaled corticosteroids are commonly used for lung inflammations despite their considerable side effects. By utilizing particle engineering techniques, a combined dry powder inhaler (DPI) comprising nanosized ketoprofen-embedded mannitol-coated microparticles was developed. A nanoembedded microparticle system means a novel advance in pulmonary delivery by enhancing local pulmonary deposition while avoiding clearance mechanisms...
January 7, 2024: Pharmaceuticals
https://read.qxmd.com/read/38111626/expert-group-recommendation-on-inhaled-mucoactive-drugs-in-pediatric-respiratory-diseases-an-indian-perspective
#2
REVIEW
Meenu Singh, Sneha Varkki, Ilin Kinimi, Rashmi R Das, Jagdish Prasad Goyal, Mushtaq Bhat, Rajeshwar Dayal, Pawan Kalyan, Jitender Gairolla, Indu Khosla
BACKGROUND: Currently, there are no guidelines or consensus statements about the usage of inhaled mucoactive drugs in pediatric respiratory disease conditions from an Indian perspective. OBJECTIVE: To develop a practical consensus document to help pediatricians in clinical decision-making when choosing an appropriate mucoactive drug for the management of specific respiratory disease conditions. METHODS: A committee of nine experts with significant experience in pediatric respiratory disease conditions and a microbiological expert constituted the panel...
2023: Frontiers in Pediatrics
https://read.qxmd.com/read/38013123/development-and-characterization-of-a-spray-dried-inhalable-ternary-combination-for-the-treatment-of-pseudomonas-aeruginosa-biofilm-infection-in-cystic-fibrosis
#3
JOURNAL ARTICLE
Nasser Alhajj, Mohd Fakharul Zaman Raja Yahya, Niall J O'Reilly, Helen Cathcart
Cystic fibrosis (CF) is an inherited lung disease characterised by the accumulation of thick layers of dried mucus in the lungs which serve as a nidus for chronic infection. Pseudomonas aeruginosa is the predominant cause of chronic lung infection in cystic fibrosis. The dense mucus coupled with biofilm formation hinder antibiotic penetration and prevent them from reaching their target. Mucoactive agents are recommended in the treatment of CF in combination with antibiotics. In spite of the extensive research in developing novel drug combinations for the treatment of lung infection in CF, to our knowledge, there is no study that combines antibiotic, antibiofilm and mucoactive agent in a single inhaled dry powder formulation...
November 25, 2023: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/37658311/a-systematic-review-of-the-clinical-impact-of-small-colony-variants-in-patients-with-cystic-fibrosis
#4
JOURNAL ARTICLE
Harrigan Ryan, Emma Ballard, Rebecca E Stockwell, Christine Duplancic, Rachel M Thomson, Kimberley Smith, Scott C Bell
BACKGROUND: Cystic fibrosis (CF) is a life-limiting disorder that is characterised by respiratory tract inflammation that is mediated by a range of microbial pathogens. Small colony variants (SCVs) of common respiratory pathogens are being increasingly recognised in CF. The aim of this systematic review is to investigate the prevalence of SCVs, clinical characteristics and health outcomes for patients with CF, and laboratory diagnostic features of SCVs compared to non-small colony variants (NCVs) for a range of Gram-positive and Gram-negative respiratory pathogens...
September 1, 2023: BMC Pulmonary Medicine
https://read.qxmd.com/read/37319354/nebulised-hypertonic-saline-for-cystic-fibrosis
#5
REVIEW
Peter Wark, Vanessa M McDonald, Sherie Smith
BACKGROUND: Hypertonic saline enhances mucociliary clearance and may lessen the destructive inflammatory process in the airways. This is an update of a previously published review. OBJECTIVES: To investigate efficacy and tolerability of nebulised hypertonic saline treatment in people with cystic fibrosis (CF) compared to placebo or other treatments that enhance mucociliary clearance. SEARCH METHODS: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register, comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings...
June 14, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/36990700/-chinese-experts-consensus-statement-diagnosis-and-treatment-of-cystic-fibrosis-2023
#6
JOURNAL ARTICLE
(no author information available yet)
Cystic fibrosis (CF) is one of the most common autosomal recessive genetic diseases in Caucasians, but CF patients in China are rare, and it was listed as the first batch of rare diseases in China in 2018. In recent years, CF has been gradually recognized in China, and the number of CF patients reported in China in the past 10 years is more than 2.5 times the total number in the previous 30 years, and the total number of CF patients is estimated to be more than 20 000. The research progress of CF gene modification has led to the innovation of CF treatment...
April 12, 2023: Chinese Journal of Tuberculosis and Respiratory Diseases
https://read.qxmd.com/read/36839867/preparation-and-characterization-of-ibuprofen-containing-nano-embedded-microparticles-for-pulmonary-delivery
#7
JOURNAL ARTICLE
Petra Party, Márk László Klement, Piroska Szabó-Révész, Rita Ambrus
A fatal hereditary condition, cystic fibrosis (CF) causes severe lung problems. Ibuprofen (IBU), a non-steroidal anti-inflammatory drug, slows the progression of disease without causing significant side effects. Considering the poor water-solubility of the drug, IBU nanoparticles are beneficial for local pulmonary administration. We aimed to formulate a carrier-free dry powder inhaler containing nanosized IBU. We combined high-performance ultra-sonication and nano spray-drying. IBU was dissolved in ethyl acetate; after that, it was sonicated into a polyvinyl alcohol solution, where it precipitated as nanoparticles...
February 6, 2023: Pharmaceutics
https://read.qxmd.com/read/36384182/boosting-lung-accumulation-of-gallium-with-inhalable-nano-embedded-microparticles-for-the-treatment-of-bacterial-pneumonia
#8
JOURNAL ARTICLE
Gabriella Costabile, Emma Mitidieri, Daniela Visaggio, Romina Provenzano, Agnese Miro, Fabiana Quaglia, Ivana d'Angelo, Emanuela Frangipani, Raffaella Sorrentino, Paolo Visca, Roberta d'Emmanuele di Villa Bianca, Francesca Ungaro
The potential of intra-venous gallium nitrate (GaN) administration against Pseudomonas aeruginosa pneumonia was recently demonstrated in mice and in cystic fibrosis (CF) patients. Likewise, the added value of direct lung delivery of Ga(III) has been shown in rats. Therefore, the design of a drug delivery system specifically engineered for Ga(III) inhalation is imperative to improve its accumulation in lungs. To this purpose, Ga(III) was efficiently encapsulated into hyaluronic acid/chitosan nanoparticles (Ga_HA/CS NPs), whose features were tuned to facilitate access to the target by overcoming mucus and biofilm surrounding bacteria...
November 13, 2022: International Journal of Pharmaceutics
https://read.qxmd.com/read/35927765/dornase-alfa-in-cystic-fibrosis-indications-comparative-studies-and-effects-on-lung-clearance-index
#9
REVIEW
Vito Terlizzi, Chiara Castellani, Giovanni Taccetti, Beatrice Ferrari
Cystic fibrosis (CF) is the most common inherited disease in Caucasian populations, affecting around 50,000 patients in Europe and 30,000 in United States. A mutation in CF trans-membrane conductance regulator (CFTR) gene changes a protein (a regulated chloride channel), which is expressed in many tissues. Defective CFTR results in reduced chloride secretion and an overage absorption of sodium across the epithelia, leading to thickened secretions in organs such as pancreas and lung. Gradually, there have been considerable improvements in the survival of people with CF, thanks to substantial changes in specialized CF care and the discovery of new CFTR modulators drugs...
August 4, 2022: Italian Journal of Pediatrics
https://read.qxmd.com/read/35676769/the-effect-of-probiotic-administration-on-metabolomics-and-glucose-metabolism-in-cf-patients
#10
JOURNAL ARTICLE
Michal Gur, Nehama Zuckerman-Levin, Kamal Masarweh, Moneera Hanna, Luca Laghi, Massimiliano Marazzato, Shir Levanon, Fahed Hakim, Ronen Bar-Yoseph, Michael Wilschanski, Lea Bentur
BACKGROUND AND OBJECTIVES: Cystic fibrosis (CF)-related diabetes (CFRD) affects 50% of CF adults. Gut microbial imbalance (dysbiosis) aggravates their inflammatory response and contributes to insulin resistance (IR). We hypothesized that probiotics may improve glucose tolerance by correcting dysbiosis. METHODS: A single-center prospective pilot study assessing the effect of Vivomixx® probiotic (450 billion/sachet) on clinical status, spirometry, lung clearance index (LCI), and quality of life (QOL) questionnaires; inflammatory parameters (urine and stool metabolomics, blood cytokines); and glucose metabolism (oral glucose tolerance test [OGTT]), continuous glucose monitoring [CGM], and homeostasis model assessment of IR (HOMA-IR) in CF patients...
October 2022: Pediatric Pulmonology
https://read.qxmd.com/read/34987088/inhaled-medicines-past-present-and-future
#11
REVIEW
Sandra Anderson, Paul Atkins, Per Bäckman, David Cipolla, Andrew Clark, Evangelia Daviskas, Bernd Disse, Plamena Entcheva-Dimitrov, Rick Fuller, Igor Gonda, Hans Lundbäck, Bo Olsson, Jeffry Weers
The purpose of this review is to summarize essential pharmacological, pharmaceutical, and clinical aspects in the field of orally inhaled therapies that may help scientists seeking to develop new products. After general comments on the rationale for inhaled therapies for respiratory disease, the focus is on products approved approximately over the last half a century. The organization of these sections reflects the key pharmacological categories. Products for asthma and chronic obstructive pulmonary disease include β -2 receptor agonists, muscarinic acetylcholine receptor antagonists, glucocorticosteroids, and cromones as well as their combinations...
January 2022: Pharmacological Reviews
https://read.qxmd.com/read/34734503/utility-of-cough-provocation-tests-in-chronic-cough-and-respiratory-diseases-a-comprehensive-review-and-introduction-of-new-reference-ranges-for-the-capsaicin-test
#12
REVIEW
Heikki Olavi Koskela, Hanna Maria Nurmi, Surinder Singh Birring
Cough provocation tests (CPTs) are an objective measurement of the sensitivity of the cough reflex arc. However, they are not established in clinical practice because a large variability of response in healthy subjects limits their diagnostic value. There is a paucity of studies that have investigated CPT reference ranges in healthy subjects. This systematic review describes the variability of the responses to CPTs in healthy subjects and factors that influence it. A new analysis of 134 healthy subjects was conducted to create reference ranges for single-breath capsaicin CPT by calculating the interquartile ranges for the provocative concentration of capsaicin to induce 2 and 5 coughs...
November 2021: Allergy, Asthma & Immunology Research
https://read.qxmd.com/read/34687284/comparison-of-inhaled-mannitol-dornase-alfa-combination-and-daily-dornase-alfa-alone-in-children-with-cystic-fibrosis
#13
JOURNAL ARTICLE
Dilber Ademhan Tural, Ebru Yalçın, Nagehan Emiralioglu, Beste Ozsezen, Birce Sunman, Halime Nayir Buyuksahin, Ismail Guzelkas, Deniz Dogru, Ugur Ozcelik, Nural Kiper
OBJECTIVES: Inhaled recombinant human deoxyribonuclease (dornase alfa) and osmotic agents such as inhaled mannitol are used for improving the clearance of secretions of cystic fibrosis (CF) patients. We aimed to evaluate the long-term clinical effects of adding dry powder inhaled (DPI) mannitol in subjects with CF who are taking daily dornase alfa. METHOD: We conducted a retrospective case-control study on subjects with CF. The effect of DPI mannitol was assessed by comparing DPI mannitol and dornase alfa combination with daily dornase alfa alone in children with CF during a 12-month period...
January 2022: Pediatric Pulmonology
https://read.qxmd.com/read/34362426/hypertonic-saline-in-people-with-cystic-fibrosis-review-of-comparative-studies-and-clinical-practice
#14
JOURNAL ARTICLE
Vito Terlizzi, Eleonora Masi, Michela Francalanci, Giovanni Taccetti, Diletta Innocenti
Cystic fibrosis (CF) is a multisystem disorder, caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. These cause a reduced secretion of chloride, a marked absorption of sodium and, therefore, of water, through the epithelium, resulting in the formation of thickened secretions in organs such as lung or pancreas. These viscous secretions lead to airway obstruction, chronic infection and inflammation resulting in progressive lung damage, bronchiectasis and eventual respiratory failure...
August 6, 2021: Italian Journal of Pediatrics
https://read.qxmd.com/read/34358540/the-rough-inhalable-ciprofloxacin-hydrochloride-microparticles-based-on-silk-fibroin-for-non-cystic-fibrosis-bronchiectasis-therapy-with-good-biocompatibility
#15
JOURNAL ARTICLE
Ling Lin, Yixian Zhou, Guilan Quan, Xin Pan, Chuanbin Wu
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory disease, and the thick and viscous mucus covering on respiratory epithelia can entrap the inhaled drugs, resulting in compromised therapeutic efficiency. In order to solve this problem, the inhalable ciprofloxacin hydrochloride microparticles (CMs) based on silk fibroin (SF) and mannitol (MAN) were designed and developed. SF was applied to increase the loading efficiency of ciprofloxacin hydrochloride by strong electrostatic interactions. MAN could facilitate the penetration of drugs through mucus, which ensured the drugs could reach their targets before clearance...
August 3, 2021: International Journal of Pharmaceutics
https://read.qxmd.com/read/34101719/inhaled-mannitol-bronchitol-for-cystic-fibrosis
#16
RANDOMIZED CONTROLLED TRIAL
(no author information available yet)
No abstract text is available yet for this article.
May 31, 2021: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/34089796/pulmonary-biofilm-based-chronic-infections-and-inhaled-treatment-strategies
#17
REVIEW
Li Ding, Jieliang Wang, Shihao Cai, Hugh Smyth, Zhengrong Cui
Certain pulmonary diseases, such as cystic fibrosis (CF), non-CF bronchiectasis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia, are usually accompanied by respiratory tract infections due to the physiological alteration of the lung immunological defenses. Recurrent infections may lead to chronic infection through the formation of biofilms. Chronic biofilm-based infections are challenging to treat using antimicrobial agents. Therefore, effective ways to eradicate biofilms and thus relieve respiratory tract infection require the development of efficacious agents for biofilm destruction, the design of delivery carriers with biofilm-targeting and/or penetrating abilities for these agents, and the direct delivery of them into the lung...
July 15, 2021: International Journal of Pharmaceutics
https://read.qxmd.com/read/33735508/dornase-alfa-for-cystic-fibrosis
#18
JOURNAL ARTICLE
Connie Yang, Mark Montgomery
BACKGROUND: Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in the lungs, promoting improved clearance of secretions. This is an update of a previously published review. OBJECTIVES: To determine whether the use of dornase alfa in cystic fibrosis is associated with improved mortality and morbidity compared to placebo or other medications that improve airway clearance, and to identify any adverse events associated with its use...
March 18, 2021: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/33715994/efficacy-and-safety-of-inhaled-dry-powder-mannitol-in-adults-with-cystic-fibrosis-an-international-randomized-controlled-study
#19
RANDOMIZED CONTROLLED TRIAL
Patrick A Flume, Elena Amelina, Cori L Daines, Brett Charlton, Joanna Leadbetter, Alessandro Guasconi, Moira L Aitken
BACKGROUND: Mannitol is a mucoactive hyperosmotic agent used as add-on therapy in patients with cystic fibrosis (CF), administered twice-daily (BID) via a small, portable, breath-actuated dry-powder inhaler. This study was conducted to provide confirmatory evidence of mannitol's efficacy and safety in adults. METHODS: This multicenter, double-blind, randomized, parallel-group, controlled clinical trial recruited adults (aged ≥18 years) with CF, and forced expiratory volume in 1 second (FEV1 ) 40-90% predicted...
November 2021: Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society
https://read.qxmd.com/read/32985670/epithelial-barrier-properties-of-the-16hbe14o-human-bronchial-epithelial-cell-culture-model
#20
JOURNAL ARTICLE
Patrick Callaghan, Bryan Ferrick, Elizabeth Rybakovsky, Sunil Thomas, James Mullin
The human bronchial epithelial cell line, 16HBE14o- (16HBE), is widely used as a model for respiratory epithelial diseases and barrier function. During differentiation, transepithelial electrical resistance (TER) increased to approximately 800 ohms x cm2 while 14C-D-mannitol flux rates (Jm) simultaneously decreased. Tight junctions were shown by diffusion potential studies to be anion selective with PC1/PNa = 1.9. Transepithelial leakiness could be induced by the phorbol ester, protein kinase C activator, 12-O-tetradecanoylphorbol-13-acetate (TPA), and the proinflammatory cytokine, Tumor Necrosis Factor-α (TNF-α)...
September 28, 2020: Bioscience Reports
keyword
keyword
160612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.